top of page

Tissue biomarkers


Accumulation of copy number alterations and clinical progression across advanced prostate cancer

Grist E, et al. Genome Medicine. 2022

Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial

Feng F, et al. JAMA Oncol. 2021

Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial

Gilson C, et al. JCO Precision Oncology. 2020

Improvements in radiographic progression-free survival stratified by ERG gene status in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.

Attard G, et al. Clin Cancer Res. 2015

Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.

Richards J, et al. Cancer Res. 2012

bottom of page